Market Overview & Estimation
The Short Bowel Syndrome (SBS) market is experiencing rapid growth, with a projected CAGR of 15.9% between 2023 and 2030. This therapeutic landscape is driven by the increasing incidence of gastrointestinal disorders such as Crohn’s disease, volvulus, and mesenteric ischemia, often requiring surgical resection of the small intestine. The lack of sufficient absorption capacity leads to debilitating complications—malnutrition, diarrhea, electrolyte imbalance, and chronic dependence on parenteral nutrition (PN). For sample report, click on Short Bowel Syndrome
Patients on PN incur annual costs ranging from USD 150,000 to USD 586,000, highlighting the economic burden and fueling the greater uptake of GLP-2 analog drugs aimed at improving intestinal absorption.
Latest News & Market Trends
The SBS market has witnessed several exciting developments:
Clinical Progress in GLP-2 & GLP-1 Therapies
VectivBio’s apraglutide has advanced to Phase 3 trials under the STARS study, offering once-weekly dosing and remnant bowel-suited treatment—potentially reducing PN dependence. Similarly, 9 Meters Biopharma recently reported positive topline results from its Phase 1b/2a trial of NM‑002, a GLP‑1 receptor agonist engineered to slow gut transit and improve nutrient absorption.
Advances in Surgical Techniques
Innovations like STEP (Serial Transverse Enteroplasty), the Bianchi procedure, and Autologous Intestinal Reconstruction Surgery (AIRS) are redefining treatment paradigms. These interventions extend the functional length of the intestine, reducing PN reliance.
Increasing Awareness & Policy Support
Public awareness campaigns, coupled with inclusion in rare disease treatment frameworks, are enhancing early diagnosis. Regulatory bodies have expanded indications for SBS drugs—such as pediatric use for teduglutide—making treatment more accessible.
Market Segmentation
By Drug Class
GLP‑2 analogs dominate the market due to the early entry of products like Gattex/teduglutide. These agents help improve intestinal absorption, thus reducing PN use. Growth hormone and glutamine therapies are present but remain the minority due to limited long-term benefits. The GLP‑2 segment holds the largest share, bolstered by patent protection and therapeutic efficacy.
By Distribution Channel
Treatment distribution is primarily via hospital and retail pharmacies, where patients typically obtain chronic medications. Hospital pharmacies handle initial and high-dose regimens, while retail pharmacies support long-term outpatient supply—supporting continued adherence and patient convenience.
By Geography
North America holds the largest share thanks to early drug approvals and transition into pediatric care. Asia-Pacific is the fastest-growing region, bolstered by Korea, India, and emerging economies investing in GI health infrastructure and disease awareness.
4. Regional Analysis: United States & Japan
United States
The U.S. SBS market is expected to grow at a CAGR of 8.9% from 2023 to 2033, with substantial investment in GLP‑2 drugs and expanded hospital usage. Around 10,000–20,000 patients suffer from Crohn’s-related SBS, and federal programs are accelerating access. Hospital pharmacies lead in distribution, though home-based specialty pharmacies are on the rise.
Japan
Japan is an active player within the Asia‑Pacific region, leveraging its robust IBD research, orphan drug pathways, and growing navigation of pediatric SBS treatment. While precise market values are not published, government support and rising GI disorder awareness position Japan as a high-growth, strategic market for GLP‑2 therapies
5. Key Highlights
An estimated CAGR of 15.9% from 2023 to 2030 indicates exponential market growth.
Exact forecasted market figures through 2030 are proprietary, but current valuations suggest billions in annual global spend.
Asia‑Pacific is the fastest-growing region, with North America retaining dominance.
PN therapy costs reaching half a million dollars per patient annually underscore the need for efficient drug alternatives.
Surgical innovation in bowel lengthening and modern GLP therapies signal a shift toward integrative, multi-modal care.
6. Key Players & Competitive Landscape
Five leading market players with substantial market share and growth momentum include:
Takeda Pharmaceutical Company – Maker of teduglutide (Gattex/Revestive), with expanded indications and global reach.
OxThera Inc. – Developing novel therapies for nutrient absorption and GI function.
VectivBio AG – Leading clinical trials with apraglutide, a next-gen GLP-2 analog.
Merck KGaA – Strong in GI therapeutics, with growth strategies in SBS pipelines.
Pfizer Inc. – Active in nutritional support and rare GI conditions with ongoing development plans.
Other significant players include Nutrinia, Ardelyx, Zealand Pharma, and Nestlé Health Science, with the market driven by alliances, licensing agreements, and clinical trial progress.
About Us
DataM Intelligence is a global market research and consulting firm delivering data-driven insights across healthcare, pharmaceuticals, and biotechnology. Its Short Bowel Syndrome market report offers detailed segmentation, competitive analysis, and executable market intelligence.
Contact Us
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: datamintelligence.com
